Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study

Duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ and -γ, was evaluated in a Phase 1 study in advanced hematologic malignancies, which included expansion cohorts in relapsed/refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and treat...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Am J Hematol
Hoofdauteurs: O’Brien, Susan, Patel, Manish, Kahl, Brad S., Horwitz, Steven M., Foss, Francine M., Porcu, Pierluigi, Jones, Jeffrey, Burger, Jan, Jain, Nitin, Allen, Kerstin, Faia, Kerrie, Douglas, Mark, Stern, Howard M., Sweeney, Jennifer, Kelly, Patrick, Kelly, Virginia, Flinn, Ian
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2018
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8260004/
https://ncbi.nlm.nih.gov/pubmed/30094870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25243
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items